此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

前列腺癌大分割全骨盆放疗 (WPRT) 与常规分割 WPRT (HOPE)

在前列腺癌患者中,大分割全骨盆放疗 (WPRT) 是否与常规分割 WPRT 一样耐受? (HOPE-试用版)

The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.

This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).

研究概览

研究类型

介入性

注册 (估计的)

58

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 4N2
        • Tom Baker Cancer Centre
    • British Columbia
      • Kelowna、British Columbia、加拿大、V1Y 5L3
        • BC Cancer
    • Ontario
      • London、Ontario、加拿大、N6A 5W9
        • London Regional Cancer Program of the Lawson Health Research Institute

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  • Age 18 or older
  • Study Informed Consent provided
  • Pathologically proven diagnosis of prostatic adenocarcinoma
  • Unfavorable intermediate risk [with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification [Prostatic Specific Antigen (PSA) > 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10]
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy

Exclusion Criteria:

  • Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
  • Plan for adjuvant docetaxel post-radiotherapy
  • Serious medical comorbidities or other contraindications to HDR-BT
  • Presence of inflammatory bowel disease
  • Presence of connective tissue disease
  • Medically unfit for general anesthesia
  • Unable or unwilling to complete questionnaires

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
有源比较器:Conventionally-fractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 45 Gy in 25 fractions WPRT

实验性的:Hypofractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 25 Gy in 5 fractions WPRT

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Quality of Life (QOL) - late bowel function as measured by the EPIC questionnaire
大体时间:I year post treatment (approximately 3 years and 2 months)

Late bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)

次要结果测量

结果测量
措施说明
大体时间
Quality of Life - acute urinary and sexual QOL as measured by the EPIC questionnaire
大体时间:6 weeks post treatment (approximately 2 years and 3 months)

Acute urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) urinary and sexual domains. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - acute bowel toxicity as measured by the EPIC questionnaire
大体时间:6 weeks post treatment (approximately 2 years and 3 months)

Acute bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) approximately 6 weeks after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - late bowel bother as measured by the EPIC questionnaire
大体时间:I year post treatment (approximately 3 years and 2 months)

Late bowel bother as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
Quality of Life - late urinary and sexual QOL as measured by the EPIC questionnaire
大体时间:I year post treatment (approximately 3 years and 2 months)

Late urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC). The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
International Prostate Symptom Score (IPSS)
大体时间:6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

International Prostate Symptom Score (IPSS) as reported by the patient at 6 weeks, 1 year, and 2 years post treatment. The IPSS is a tool used for monitoring symptoms of prostate enlargement (benign prostatic hyperplasia). There are 7 questions related to urinary function. Responses are on a scale from 0 (best) to 5 (worst). Responses are added to come up with a total score, measuring if the patient is mildly symptomatic, moderately symptomatic, or severely symptomatic. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 (best) to 6 (worst).

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0
大体时间:6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

Urinary, bowel, and sexual toxicity will be measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4, at 6 weeks, 1 year, and 2 years post treatment.

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Prostatic Specific Antigen (PSA) curve
大体时间:4 years post treatment (approximately 6 years and 2 months)

PSA curve at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Prostatic Specific Antigen (PSA) Nadir
大体时间:4 years post treatment (approximately 6 years and 2 months)

PSA nadir at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Cost Effectiveness of Hypofractionated WPRT
大体时间:End of study (approximately 7 years and 2 months)

Cost effectiveness analysis of the hypofractionated arm in comparison to the conventionally fractionated treatment arm.

End of study (approximately 7 years and 2 months)
Overall Survival
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to death from any cause.

End of study (approximately 7 years and 2 months)
Biochemical Failure-Free Survival
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to biochemical failure (based on the Phoenix definition) or death from any cause, whichever occurs first.

End of study (approximately 7 years and 2 months)
Freedom from Local Failure
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to first local failure.

End of study (approximately 7 years and 2 months)
Freedom from Regional Failure
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to first regional failure.

End of study (approximately 7 years and 2 months)
Androgen Deprivation Therapy Free Survival
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to start of salvage ADT, death or last follow-up.

End of study (approximately 7 years and 2 months)
Metastasis Free Survival
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to development of metastasis, death or last follow-up.

End of study (approximately 7 years and 2 months)
Prostate Cancer Free Survival
大体时间:End of study (approximately 7 years and 2 months)

The time from randomization to death attributed to prostate cancer.

End of study (approximately 7 years and 2 months)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lucas C Mendez, MD、London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年2月7日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2028年3月1日

研究注册日期

首次提交

2019年12月6日

首先提交符合 QC 标准的

2019年12月11日

首次发布 (实际的)

2019年12月12日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅